LP
BNTC icon

Longaeva Partners’s Benitec Biopharma BNTC Stock Holding History

Longaeva Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Sell
125,000
-165,000
-57% -$1.91M 0.05% 165
2025
Q4 		$3.91M Buy
290,000
+252,463
+673% +$3.49M 0.33% 69
2025
Q3 		$527K Sell
37,537
-14,460
-28% -$185K 0.08% 68
2025
Q2 		$608K Sell
51,997
-28,003
-35% -$392K 0.12% 48
2025
Q1 		$1.04M Buy
+80,000
New +$968K 0.59% 17

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Longaeva Partners's BNTC Position: Q1 2026 in Review

Longaeva Partners reduced its Benitec Biopharma (BNTC) stake by 57% in Q1 2026, selling an estimated $1.91M and leaving 125,000 shares worth $1.33M. The position accounts for 0.05% of the portfolio, ranked #165.

Longaeva Partners first reported a position in BNTC in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.91M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Longaeva Partners held 125,000 shares of Benitec Biopharma worth $1.33M as of Q1 2026.
  • Longaeva Partners sold 165,000 Benitec Biopharma shares in Q1 2026, an estimated $1.91M.
  • Benitec Biopharma made up 0.05% of Longaeva Partners's portfolio in Q1 2026, its #165 holding.
  • Longaeva Partners first reported a position in Benitec Biopharma in Q1 2025 and has held it in 5 quarters since.
  • Longaeva Partners's Benitec Biopharma position peaked at $3.91M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.